Literature DB >> 8983589

Risk factors and dose-effect relationship for osteoradionecrosis after hyperfractionated and conventionally fractionated radiotherapy for oral cancer.

M Niewald1, O Barbie, K Schnabel, M Engel, M Schedler, C Nieder, W Berberich.   

Abstract

A high frequency of osteoradionecrosis after hyperfractionated radiotherapy (RT) of head and neck tumours led to a detailed analysis of risk factors in the dental, surgical, and radiotherapeutic areas. 168 patients with oral cancer were analysed retrospectively. 19% of them had been irradiated primarily and 81% postoperatively. 116 patients received a total dose mostly ranging from 60 Gy to 70 Gy to the ICRU 29 reference point (daily single dose 2 Gy). 52 patients were treated hyperfractionally with two daily fractions of 1.2 Gy per day, 4 h minimum apart and a total dose 82.8 Gy. Dental findings could be evaluated in 126 patients. Factors were checked for prognostic significance for osteoradionecrosis (ORN). Dose dependency was computed using a PROBIT analysis. Dental status before radiotherapy was generally poor (mean 11/32 teeth present, of these 1 was dead, 2.4 carious, 2.4 loose, 0.3 destroyed). On average, six teeth (range 0-27 teeth) had to be extracted. In one-third of the patients bone surgery was necessary. ORN occurred in 8.6% of the patients treated conventionally but in 22.9% of those treated hyperfractionally (p = 0.029). Biologically effective dose (p = 0.032) and deep paradontitis (p = 0.034) proved to be significant risk factors for ORN. PROBIT analysis showed a steadily rising dose dependency of the ORN frequency after conventional radiotherapy. Using total doses up to 70 Gy the frequency of ORN was 8.6%. Dose escalation using hyperfractionation led to an intolerable ORN frequency (22.9%) where a short interfraction interval was a significant factor. The use of this dose fractionation was therefore discontinued in 1992.

Entities:  

Mesh:

Year:  1996        PMID: 8983589     DOI: 10.1259/0007-1285-69-825-847

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  6 in total

1.  Osteoradionecrosis of the cervical vertebrae in patients irradiated for head and neck cancers.

Authors:  Yasuhiro Kosaka; Yoshishige Okuno; Yumiko Tagawa; Nami Ueki; Kyo Itoh; Shogo Shinohara; Masahiro Kikuchi
Journal:  Jpn J Radiol       Date:  2010-06-30       Impact factor: 2.374

Review 2.  Oral and dental late effects in survivors of childhood cancer: a Children's Oncology Group report.

Authors:  Karen E Effinger; Cesar A Migliorati; Melissa M Hudson; Kevin P McMullen; Sue C Kaste; Kathy Ruble; Gregory M T Guilcher; Ami J Shah; Sharon M Castellino
Journal:  Support Care Cancer       Date:  2014-04-30       Impact factor: 3.603

3.  Effects of age and radiation treatment on function of extrinsic tongue muscles.

Authors:  John A Russell; Nadine P Connor
Journal:  Radiat Oncol       Date:  2014-12-04       Impact factor: 3.481

4.  Frequency of osteoradionecrosis of the lower jaw after radiotherapy of oral cancer patients correlated with dosimetric parameters and other risk factors.

Authors:  Kristin Lang; Thomas Held; Eva Meixner; Eric Tonndorf-Martini; Oliver Ristow; Julius Moratin; Nina Bougatf; Christian Freudlsperger; Jürgen Debus; Sebastian Adeberg
Journal:  Head Face Med       Date:  2022-02-26       Impact factor: 2.151

5.  Dental status, dental rehabilitation procedures, demographic and oncological data as potential risk factors for infected osteoradionecrosis of the lower jaw after radiotherapy for oral neoplasms: a retrospective evaluation.

Authors:  Marcus Niewald; Jochen Fleckenstein; Kristina Mang; Henrik Holtmann; Wolfgang J Spitzer; Christian Rübe
Journal:  Radiat Oncol       Date:  2013-10-02       Impact factor: 3.481

6.  Dental status, dental treatment procedures and radiotherapy as risk factors for infected osteoradionecrosis (IORN) in patients with oral cancer - a comparison of two 10 years' observation periods.

Authors:  Marcus Niewald; Kristina Mang; Oliver Barbie; Jochen Fleckenstein; Henrik Holtmann; Wolfgang J Spitzer; Christian Rübe
Journal:  Springerplus       Date:  2014-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.